Could Alcon (ALC) and RxSight (RXST)’s Partnership Reshape the Future of Cataract Surgery?
RxSight (RXST) Q2 2026 Earnings Call Transcript
Stifel Maintains Hold on RxSight, Lowers Price Target to $7
UBS Maintains Neutral on RxSight, Raises Price Target to $6.3
RxSight Inc (RXST) (Q2 2026) Earnings Call Highlights: Strategic Pivot Amid Revenue Decline and ...
RxSight Q2 Earnings Call Highlights
RxSight, Inc. (RXST) Q2 2026 Earnings Call Transcript
RxSight (NASDAQ:RXST) Slips After Q2 Revenue Matches, Loss Narrows
RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook
Earnings Preview: RxSight, Inc. (RXST) Q2 Earnings Expected to Decline
RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
RxSight (RXST) Surges 6.1%: Is This an Indication of Further Gains?
RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer
RxSight Appoints Aziz Mottiwala President, CEO, Effective July 20, Succeeding Ron Kurtz
RxSight Q2 Sales Sink 20% as Alcon Deal Bolsters 2026 Outlook
RxSight: Alcon Deal Reshapes The Long-Term Growth Story
B of A Securities Maintains Underperform on RxSight, Lowers Price Target to $6.5
Needham Reiterates Buy on RxSight, Maintains $11 Price Target
Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.